Sande Christopher M, Chen Stone, Mitchell Dana V, Lin Ping, Abraham Diana M, Cheng Jessie Minxuan, Gebhard Talia, Deolikar Rujul J, Freeman Colby, Zhou Mary, Kumar Sushant, Bowman Michael, Bowman Robert L, Zheng Shannon, Munkhbileg Bolormaa, Chen Qijun, Stanley Natasha L, Guo Kathy, Lapite Ajibike, Hausler Ryan, Taylor Deanne M, Corines James, Morrissette Jennifer Jd, Lieberman David B, Yang Guang, Shestova Olga, Gill Saar, Zheng Jiayin, Smith-Simmer Kelcy, Banaszak Lauren G, Shoger Kyle N, Reinig Erica F, Peterson Madilynn, Nicholas Peter, Walne Amanda J, Dokal Inderjeet, Rosenheck Justin P, Oetjen Karolyn A, Link Daniel C, Gelman Andrew E, Reilly Christopher R, Dutta Ritika, Lindsley R Coleman, Brundige Karyn J, Agarwal Suneet, Bertuch Alison A, Churpek Jane E, Tague Laneshia K, Johnson F Brad, Olson Timothy S, Babushok Daria V
Department of Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Department of Laboratories, Seattle Children's Hospital, Seattle, Washington, USA.
J Clin Invest. 2025 Apr 3;135(8). doi: 10.1172/JCI181659. eCollection 2025 Apr 15.
Telomere biology disorders (TBDs) are genetic diseases caused by defective telomere maintenance. TBD patients often develop bone marrow failure and have an increased risk of myeloid neoplasms. To better understand the factors underlying hematopoietic outcomes in TBD, we comprehensively evaluated acquired genetic alterations in hematopoietic cells from 166 pediatric and adult TBD patients. Of these patients, 47.6% (28.8% of children, 56.1% of adults) had clonal hematopoiesis. Recurrent somatic alterations involved telomere maintenance genes (7.6%), spliceosome genes (10.4%, mainly U2AF1 p.S34), and chromosomal alterations (20.2%), including 1q gain (5.9%). Somatic variants affecting the DNA damage response (DDR) were identified in 21.5% of patients, including 20 presumed loss-of-function variants in ataxia-telangiectasia mutated (ATM). Using multimodal approaches, including single-cell sequencing, assays of ATM activation, telomere dysfunction-induced foci analysis, and cell-growth assays, we demonstrate telomere dysfunction-induced activation of the ATM-dependent DDR pathway with increased senescence and apoptosis in TBD patient cells. Pharmacologic ATM inhibition, modeling the effects of somatic ATM variants, selectively improved TBD cell fitness by allowing cells to bypass DDR-mediated senescence without detectably inducing chromosomal instability. Our results indicate that ATM-dependent DDR induced by telomere dysfunction is a key contributor to TBD pathogenesis and suggest dampening hyperactive ATM-dependent DDR as a potential therapeutic intervention.
端粒生物学障碍(TBDs)是由端粒维持缺陷引起的遗传性疾病。TBD患者常发生骨髓衰竭,患髓系肿瘤的风险增加。为了更好地了解TBD造血结果的潜在因素,我们全面评估了166例儿科和成人TBD患者造血细胞中的获得性基因改变。在这些患者中,47.6%(儿童为28.8%,成人为56.1%)存在克隆性造血。复发性体细胞改变涉及端粒维持基因(7.6%)、剪接体基因(10.4%,主要是U2AF1 p.S34)和染色体改变(20.2%),包括1q增益(5.9%)。在21.5%的患者中鉴定出影响DNA损伤反应(DDR)的体细胞变异,包括20个共济失调毛细血管扩张突变(ATM)的假定功能丧失变异。使用多模态方法,包括单细胞测序、ATM激活测定、端粒功能障碍诱导灶分析和细胞生长测定,我们证明了端粒功能障碍在TBD患者细胞中诱导ATM依赖性DDR途径激活,同时衰老和凋亡增加。模拟体细胞ATM变异效应的药理学ATM抑制通过允许细胞绕过DDR介导的衰老而选择性地改善了TBD细胞适应性,而未检测到诱导染色体不稳定。我们的结果表明,端粒功能障碍诱导的ATM依赖性DDR是TBD发病机制的关键因素,并提示抑制过度活跃的ATM依赖性DDR作为一种潜在的治疗干预措施。